ABEO
Abeona Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.00
+1.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 25.5M | 5.8M | — | 3.5M | 1.4M |
| Cost of Revenue | 11.1M | 1.5M | 2.9M | 1.6M | 450.0K |
| Gross Profit | 14.5M | 4.3M | (2.9M) | 1.9M | 964.0K |
| Operating Expenses | |||||
| R&D Expense | 25.5M | 26.8M | 34.4M | 31.1M | 29.0M |
| SG&A Expense | 72.6M | 65.0M | 29.9M | 19.0M | 17.3M |
| General & Admin Expense | 53.9M | 65.0M | 29.9M | 19.0M | 17.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | 1.9M | (2.9M) | (1.1M) | 5.7M |
| Total Operating Expenses | 98.1M | 93.7M | 61.3M | 49.0M | 51.9M |
| Cost and Expenses | 109.1M | 95.3M | 64.2M | 50.6M | 52.3M |
| Operating Income (EBIT) | (83.6M) | (89.4M) | (64.2M) | (47.1M) | (50.9M) |
| Non-Operating | |||||
| Interest Income | 5.9M | 5.6M | 4.2M | 2.1M | 431.0K |
| Interest Expense | 3.3M | 3.7M | 4.2M | 418.0K | 736.0K |
| Net Interest Income | 2.6M | 1.8M | 38.0K | 1.7M | (305.0K) |
| Other Non-Op Income/Expense | 5.3M | 160.7M | 477.0K | (7.1M) | 11.2M |
| Non-Operating Income (excl Interest) | (8.6M) | (164.5M) | (4.7M) | 6.6M | (12.0M) |
| EBT (Pre-Tax Income) | (78.3M) | 71.3M | (63.7M) | (54.2M) | (39.7M) |
| Income Tax Expense | (15.4M) | 100.0K | — | — | — |
| Bottom Line | |||||
| Net Income | (62.9M) | 71.2M | (63.7M) | (54.2M) | (39.7M) |
| Earnings from Cont. Ops | (62.9M) | 71.2M | (63.7M) | (54.2M) | (39.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (62.9M) | 67.1M | (63.7M) | (54.2M) | (43.5M) |
| Per Share | |||||
| Basic EPS | ($1.14) | $1.34 | ($1.55) | ($2.53) | ($5.53) |
| Diluted EPS | ($1.11) | $1.01 | ($1.55) | ($2.53) | ($5.53) |
| Revenue Per Share | $0.45 | $0.11 | $0.00 | $0.16 | $0.18 |
| Shares | |||||
| Basic Shares Outstanding | 57.0M | 53.0M | 41.0M | 21.4M | 7.9M |
| Diluted Shares Outstanding | 57.0M | 66.1M | 41.0M | 21.4M | 7.9M |
| Profitability Metrics | |||||
| EBITDA | (71.4M) | 78.6M | (56.6M) | (50.6M) | (34.4M) |
| D&A | 3.5M | 3.6M | 2.9M | 3.2M | 4.6M |
| EBIT | (75.0M) | 75.0M | (59.5M) | (53.8M) | (39.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026